返回 
加入收藏
艾迪注射液联合一线化疗用于NSCLC的快速卫生技术评估
x
请在关注微信后，向客服人员索取文件
| 篇名： | 艾迪注射液联合一线化疗用于NSCLC的快速卫生技术评估 |
| TITLE： | Rapid health technology assessment of Aidi injection combined with first-line chemotherapy for non-small cell lung cancer |
| 摘要： | 目的 评价艾迪注射液联合一线化疗用于非小细胞肺癌（NSCLC）的有效性、安全性和经济性，为临床用药和决策提供循证依据。方法计算机检索PubMed、Embase、theCochraneLibrary、中国知网、万方数据、维普网及国内外卫生技术评估（HTA）机构官方网站，收集艾迪注射液联合一线化疗用于NSCLC的HTA报告、系统评价/Meta分析和药物经济学研究，检索时限均为建库起至2022年8月。资料提取和质量评价后，对纳入研究的结果进行描述性分析。结果共纳入16篇文献，其中1篇系统评价，13篇Meta分析，2篇药物经济学研究。与一线化疗相比，艾迪注射液联合一线化疗可提高NSCLC患者的有效率和疾病控制率，延长生存时间，改善生存质量，降低恶心呕吐、白细胞减少、血小板降低发生率，提高免疫功能，但对肝肾功能的影响存在争议。以2019年全国人均国内生产总值设定支付阈值，艾迪注射液联合一线化疗具有经济性。结论艾迪注射液联合一线化疗用于NSCLC的疗效和安全性均较好，且具有一定的经济性，但鉴于纳入的药物经济学研究较少，因此所得经济学结论需谨慎解读。 |
| ABSTRACT： | OBJECTIVE To evaluate the effectiveness， safety and economics of Aidi injection combined with first-line chemotherapy for non-small cell lung cancer （NSCLC）， and to provide evidence-based reference for clinical drug use and decision. METHODS Retrieved from PubMed， Embase， the Cochrane Library， CNKI， Wanfang databases， VIP and Health Technology Assessment （HTA） related websites， HTA reports， systematic evaluation/meta-analysis and economic evaluations about Aidi injection combined with first-line chemotherapy for NSCLC were collected from the inception to Aug. 2022. After data extraction and quality evaluation， descriptive analysis was performed for the results of included studies. RESULTS A total of 16 pieces of literature were included， involving 1 piece of systematic review， 13 pieces of meta-analysis， 2 pieces of pharmacoeconomic studies. Compared with first-line chemotherapy， Aidi injection combined with first-line chemotherapy could improve response rate and disease control rate， prolonged survival time， improved survival quality， reduced the incidence of nausea and vomiting， leukocytopenia and thrombocytopenia， and improved immune function， but had controversial effects on liver and kidney function. With the payment threshold set by 3 times the national per capita GDP in 2019， Aidi injection combined with first-line chemotherapy had a more economical probability. CONCLUSIONS Aidi injection combined with first-line chemotherapy for NSCLC has good efficacy and safety， and has certain economic benefits. However， given the limited pharmacoeconomic studies included， the economic conclusions obtained need to be carefully interpreted. |
| 期刊： | 2023年第34卷第10期 |
| 作者： | 许聪聪；黄柳绿；唐姣；刘盈；韩永龙 |
| AUTHORS： | XU Congcong，HUANG Liulü，TANG Jiao，LIU Ying，HAN Yonglong |
| 关键字： | 艾迪注射液；化疗；非小细胞肺癌；快速卫生技术评估；药物经济学 |
| KEYWORDS： | Aidi injection； chemotherapy； non-small cell lung cancer； rapid health technology assessment； pharmacoeconomic |
| 阅读数： | 111 次 |
| 本月下载数： | 5 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
